NYXH Nyxoah

Nyxoah Announces Inaugural Investor & Analyst Meeting

Nyxoah Announces Inaugural Investor & Analyst Meeting



Nyxoah Announces Inaugural Investor & Analyst Meeting

Mont-Saint-Guibert, Belgium – February 22, 2023, 12:00pm CET / 6:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will host its inaugural Investor & Analyst Meeting on March 23, 2023, from 4:00pm to 7:00pm ET.

The event, which will be held at Nyxoah’s New York City offices, will include a business update from the Company’s senior management and presentations from key opinion leaders in the field of obstructive sleep apnea. The meeting will conclude with a Q&A session, followed by a reception.

Investors interested in attending the meeting may do so by registering for the event at the following link: . A live and archived webcast of the event will be available on the Company’s investor relations website at .

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit .

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

David DeMartino, Chief Strategy Officer





Attachment



EN
22/02/2023

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE
Free
NYXH NYXOAH

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 23, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,430,026.16 Total number of securities carrying voting rights: 37,429,265 (all ordinary shares) Total number of voting rights (= denominator): 37,429,265 (all relating ...

May 23, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Informations sur le nombre total de droits de vote et d'actions

Informations sur le nombre total de droits de vote et d'actions Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 23 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publie les informations ci-dessous suite à l'émission de nouvelles actions. Capital: EUR 6.430.026,16  Nombre total de titres avec droits de vote: 37.429.265 (tous des actions ordinaires) Nombre total de droits de vote (= dénominateur): ...

May 23, 2025 1 EN
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
05/21/25 May 21, 2025 1 FR
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Reports First Quarter Financial and Operating Results

Nyxoah Reports First Quarter Financial and Operating Results REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported f...

May 14, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier T...

Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre La Société est en bonne voie pour obtenir l'autorisation de mise sur le marché au deuxième trimestre 2025 Les exigences de validation de la FDA ont été remplies avec succès, l'inspection finale du site est en cours Mont-Saint-Guibert, Belgique – 14 mai 2025, 07h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des al...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch